ProPhase Labs Announces Publication of BE-Smart Esophageal Cancer Study in the Official Journal of the American College of Gastroenterology (Globe Newswire)

A breakthrough study published in Clinical and Translational Gastroenterology, the official journal of the ACG, showcases ProPhase Labs’ BE-Smart — an 8-protein, mass-spectrometry-based assay that accurately predicts which Barrett’s esophagus patients are likely to develop esophageal cancer. Developed with the Mayo Clinic, BE-Smart achieved 100% sensitivity and a hazard ratio of 66, marking a major leap in molecular risk stratification. The test requires minimal tissue and works with standard biopsies, offering a scalable, next-generation approach for early cancer detection. Early access and physician programs are set to launch in early 2026.